# CAREMM-002 (NCT05979363)

> A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd)-Based Regimen Followed by BCMA CAR-T Therapy in Transplant-Ineligible Patients With Primary Plasma Cell Leukemia

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05979363
- Phase: PHASE2
- Status: RECRUITING
- Sponsor: Institute of Hematology & Blood Diseases Hospital, China
- Conditions: Plasma Cell Leukemia
- Interventions: anti-BCMA CAR-T; VRD-based regimen
- Enrollment: 20
- Primary outcome: Safety and Tolerability
- Primary outcome: MRD-negative rate

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 4

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=caremm-002-nct05979363